



For immediate release

3 March 2006

ANGEL BIOTECHNOLOGY HOLDINGS PLC
(“Angel” or “the Company”)

Joint biological scale up development contract

Angel Biotechnology Holdings plc, (AIM: ABH) the biopharmaceutical contract manufacturer, and Industrial Biotechnology Corporation (“IBC”) (OTC: IBTY) jointly announce a biological scale up development contract. Terms of the contract have not been disclosed.

Under the contract Angel will provide fermentation and scale up optimization of selected chemicals and production of samples prior to commercial production for Industrial Biotechnology Corporation.

Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings plc, said: “We are very pleased to work with IBC and their exciting new technology. We look forward to assisting IBC develop, produce and manufacture many chemicals at lower costs and with less impact to the environment than traditional chemical production methods. We are extremely confident in our team’s ability and expertise to meet their needs and deliverables”.

Dr Gurinder Shahi, Chief Technologist of IBC stated: "Angel is a perfect scale up partner for us. They have an excellent reputation and strong capabilities in areas that are synergistic to our needs. Working together, we expect to accelerate the process of bringing high value chemicals that are produced using IBC’s patented designer enzyme technology to market. Our proprietary production technologies enable the production of these chemicals biologically in mass quantities at significantly lower costs and with less impact to our environment.”

For further information, please call:

Angel Biotechnology Holdings plc
Gordon Sherriff – COO

Tel 01670 591920
Tel 07951 057016

Buchanan Communications
Lisa Baderoon/Mary-Jane Johnson

Tel 020 7466 5000

About Angel Biotechnology Holdings plc

Angel Biotechnology Holdings plc is a fast growing biomanufacturing company offering process development services and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along

with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.

Angel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo, SmithKline Beecham and Serologicals Inc.

Angel operates out of two sites, at Cramlington near Newcastle upon Tyne and at Pentlands Science Park, near Edinburgh.

Angel was established in 2000 and was admitted to trading on AIM in November 2005.

About Industrial Biotechnology Corporation

Industrial Biotechnology Corporation (“IBC”) commercializes proprietary technologies and intellectual property in the emerging field of biologically produced chemicals. We believe these technologies enable IBC to more efficiently manufacture high value chemicals at significantly lower costs, with a substantially lower environmental impact than traditional methods, and with a higher purity. Through licensing, partnerships, and direct sales via multiple distribution channels to several industries, IBC will bring to market new and established chemicals that are in high demand for use in Flavors and Fragrances, Fine chemicals, Pharmaceutical, Agricultural, Environmental and Bio-Energy applications. IBC's pioneering and state-of-the-art biological production methods can replace large manufacturing facilities, many of which employ hazardous processes, and toxic materials in their chemical production. These innovative methods involve fewer production steps, and through the use of "designer" enzymes and proprietary production systems, may enable IBC to produce greater yields of high-purity, natural compounds at significantly lower costs. We believe these processes can be readily scaled-up to large, commercial production levels. IBC's core intellectual property utilizes patented technologies exclusively licensed from Rice University. The company has assembled a team of leading scientists, management and industry leaders to implement these new technologies. IBC has a comprehensive technology and licensing acquisition strategy, and will seek to establish research and development partnerships with leading universities and corporations in the industrial biotechnology field to develop commercially viable biological-based solutions and related intellectual property patents. For more information, email us: info@industrialbiotechnology.com